Finally, a recent report in patients with metastatic melanoma and renal cell carcinoma treated with SBRT given in one, two, or three doses of 20 Gy, in combination with high dose IL-2 showed a response rate in non-irradiated lesions (abscopal responses) higher than expected with IL-2 alone (Seung et al., 2012). This evidence concerns the gene IL2 and hereditary clear cell renal cell carcinoma.